Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antibiotic Selection00:57

Antibiotic Selection

61.9K
Overview
61.9K
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

1.8K
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
1.8K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

7.2K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
7.2K
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration01:23

Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration

70
Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s...
70
Preclinical Development: Overview01:28

Preclinical Development: Overview

6.3K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.3K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1.3K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Will Mortality Rates in the Next Viral Pandemic Be Affected by the COVID-19 Experience?

The Journal of infectious diseases·2024
Same author

Multi-year analysis of the global preclinical antibacterial pipeline: trends and gaps.

Antimicrobial agents and chemotherapy·2024
Same author

Antibiotic stewardship programs should include disinfectants and biocides.

The Journal of antibiotics·2023
Same author

Reply to Kaye and Belley, "Third-Generation Cephalosporin-Resistant <i>Enterobacterales</i> Are Critical Priority Pathogens, Too!"

Antimicrobial agents and chemotherapy·2022
Same author

Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed.

Antimicrobial agents and chemotherapy·2022
Same author

Accelerated Preclinical Paths to Support Rapid Development of COVID-19 Therapeutics.

Cell host & microbe·2020

Related Experiment Video

Updated: Mar 14, 2026

Antibiotic Dereplication Using the Antibiotic Resistance Platform
10:49

Antibiotic Dereplication Using the Antibiotic Resistance Platform

Published on: October 17, 2019

11.8K

Antibiotics in late clinical development.

Prabhavathi Fernandes1, Evan Martens1

  • 1Cempra, Inc., 6320 Quadrangle Dr. Bldg 2, Chapel Hill, NC 27517, USA.

Biochemical Pharmacology
|October 1, 2016
PubMed
Summary
This summary is machine-generated.

Pharmaceutical companies are reducing antibiotic investments due to poor returns. This review highlights new antibiotics in development by smaller firms, addressing the urgent need for novel treatments against multi-drug resistant bacteria.

Keywords:
ABSSSI (acute bacterial skin and skin structure infections)Antibiotic developmentCABP (community-acquired bacterial pneumonia)New antibioticscIAI (complicated intra-abdominal infection)cUTI (complicated urinary tract infection)

More Related Videos

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.5K
Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

2.5K

Related Experiment Videos

Last Updated: Mar 14, 2026

Antibiotic Dereplication Using the Antibiotic Resistance Platform
10:49

Antibiotic Dereplication Using the Antibiotic Resistance Platform

Published on: October 17, 2019

11.8K
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.5K
Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

2.5K

Area of Science:

  • Pharmaceutical Science
  • Infectious Diseases
  • Drug Development

Background:

  • Declining investment in antibiotic discovery by major pharmaceutical companies.
  • Increasing prevalence of multi-drug resistant (MDR) bacterial infections.
  • Negative return on investment for recently approved antibiotics.

Purpose of the Study:

  • To review novel antibiotics in late-stage clinical development.
  • To identify new compounds targeting novel mechanisms against MDR bacteria.
  • To explore reasons for past failures and propose strategies to attract investment.

Main Methods:

  • Review of late-stage clinical development antibiotics.
  • Analysis of antibiotic classes and spectrum of activity.
  • Examination of factors influencing investment in antibiotic R&D.

Main Results:

  • A few small companies are actively developing new antibiotics.
  • Most new antibiotics are from existing classes; some novel compounds target new pathways.
  • Past failures linked to economic and scientific challenges.

Conclusions:

  • Despite challenges, new antibiotics are progressing through clinical development.
  • Novel compounds and strategies are needed to combat MDR infections.
  • Attracting investment is crucial for sustained antibiotic innovation.